pimobendan has been researched along with cardiovascular agents in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bossa, R; Efstathiu, G; Galatulas, I; Ninci, MA | 1 |
| Asano, R; Hosoda, S; Kitahara, K; Misu, K; Nagayama, M; Ohtaki, E; Sumiyoshi, T; Takeda, N; Tobaru, T; Umemura, J | 1 |
| Gabrielsson, J; Jirstrand, M; Martel, E; Pairet, N; Scheuerer, S; Wallman, M | 1 |
3 other study(ies) available for pimobendan and cardiovascular agents
| Article | Year |
|---|---|
Esorubicin cardiotoxicity in vitro: antagonism by pimobendan.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Doxorubicin; Electric Stimulation; Guinea Pigs; Heart; Heart Diseases; In Vitro Techniques; Pyridazines | 1990 |
Normalization of left ventricular parameters following combined pimobendan and carvedilol treatment in a case of unclassified cardiomyopathy with longstanding refractory status.
Topics: Carbazoles; Cardiomyopathies; Cardiovascular Agents; Carvedilol; Heart Failure; Humans; Male; Middle Aged; Propanolamines; Pyridazines; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2002 |
An Integrative Approach for Improved Assessment of Cardiovascular Safety Data.
Topics: Animals; Biomarkers, Pharmacological; Blood Pressure; Cardiotoxicity; Cardiovascular Agents; Heart Rate; Ivabradine; Male; Phenethylamines; Pyridazines; Rats; Rats, Wistar; Sildenafil Citrate; Sulfonamides | 2021 |